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ABSTRACT
Advanced heterologous transcription control sys-
tems for adjusting desired transgene expression are
essential for gene function assignments, drug
discovery, manufacturing of dif®cult to produce
protein pharmaceuticals and precise dosing of
gene-based therapeutic interventions. Conversion
of the Streptomyces albus heat shock response
regulator (RheA) into an arti®cial eukaryotic tran-
scription factor resulted in a vertebrate thermo-
sensor (CTA; cold-inducible transactivator), which is
able to adjust transcription initiation from chimeric
target promoters (PCTA) in a low-temperature-
inducible manner. Evaluation of the temperature-
dependent CTA±PCTA interaction using a tailored
ELISA-like cell-free assay correlated increased
af®nity of CTA for PCTA with temperature downshift.
The temperature-inducible gene regulation (TIGR)
system enabled tight repression in the chicken
bursal B-cell line DT40 at 41oC as well as precise
titration of model product proteins up to maximum
expression at or below 37oC. Implantation of
microencapsulated DT40 cells engineered for
TIGR-controlled expression of the human
vascular endothelial growth factor A (hVEGF121)
provided low-temperature-induced VEGF-mediated
vascularization in chicken embryos.
INTRODUCTION
Molecular responses to environmental temperature changes
have evolved throughout living systems. Major response
phenotypes include cold tolerance (1±3) and heat shock
phenomena (1,4±7). In prokaryotes, adaptation to elevated
temperatures may result from short-term climatic changes or
habitat switches, which are typical for human pathogenic
bacteria. The molecular basis for temperature sensing
includes (i) chaperone-mediated detection of denatured or
misfolded proteins (8); (ii) temperature-dependent allosteric
changes in thermosensors (7,9); (iii) promoter-adjusting DNA
supercoiling (10); or (iv) translation-modulating temperature-
responsive mRNA secondary structures (5,11).
In Streptomyces albus, thermotolerance is mediated by the
heat shock protein 18 (HSP18) whose expression is controlled
by a divergently encoded thermosensor RheA (12). At low
temperature, <30°C, RheA binds to a dyad symmetrical
operator (rheO) overlapping the ±35 and ±10 boxes of the
divergently oriented rheA and hsp18 promoters (PrheA and
Phsp18) and represses both genes (13). Within <1 min
following a temperature upshift to 41°C, allostery-based
disruption of the RheA±rheO interaction results in con-
comitant derepression of PrheA and Phsp18 and induction of
HSP18-mediated thermotolerance. Autoregulated RheA
expression at elevated temperatures provides high repressor
levels, which are required for immediate reversion of the
HSP18 production mode following a shift back to standard
growth temperatures (30°C) (7).
In order to evaluate whether molecular thermometers are
functional in a eukaryotic cell context, we have converted the
Streptomyces RheA±rheO interaction into a temperature-
inducible gene regulation (TIGR) system. TIGR-controlled
expression of human vascular endothelial growth factor A
(hVEGF121) in chicken bursal B cells (DT40) was silent at
41°C and could be cold induced to maximum expression
levels at 37°C. Cold-induced angiogenesis was con®rmed
in chicken embryos following implantation of micro-
encapsulated DT40 cell derivatives encoding a TIGR-based
temperature-responsive hVEGF121 expression unit.
MATERIALS AND METHODS
Plasmid construction
The cold-inducible transactivator CTA (RheA-VP16) was
constructed by cloning the S.albus G (strain J1074) rheA gene,
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ampli®ed from pOLP12B [kindly provided by P. Mazodier
(7)] by PCR using oligonucleotides OWW127: 5¢-gtacgaattcc-
caccatgaccaccgccgaccgccc-3¢ and OWW128: 5¢-gcgcgcggc-
tgtacgcggaggaccgcccggacgaggcc-3¢, digested by EcoRI±
BssHII into the corresponding sites of pWW35 (14)
(pWW251). pWW255 was constructed by cloning of PhEF1a
[excised from pWW29 (14)] digested by SspI±EcoRI into
pWW251. The cold-inducible CTA-dependent promoter
PCTA was assembled by amplifying PhCMVmin from pWW37
(14) using oligonucleotides OWW129: 5¢-gatcgacgtc-
tgtcatcgttcggatgacacctgcaggtcgagctcggtacccgggtc-3¢ [RheA-
speci®c operator site (rheO) underlined] and OWW22 (14)
and cloning it digested by AatII±EcoRI into pWW37
(pWW253). For construction of pWW254, the Bacillus
stearothermophilus-derived secreted a-amylase (SAMY)-
encoding SpeI±HindIII fragment from pSS193 (15) was
ligated (XbaI±HindIII) into pWW253. The autoregulated
SAMY expression vector pWW259 was constructed by
cloning CTA excised (SpeI±XbaI) from pWW255 into the
NheI site of pWW254. hVEGF121 was ampli®ed by RT±PCR
from a human aortic smooth muscle cell mix using
oligonucleotides OCW76: 5¢-cgcggtaccatgaactttctgctgtctt-
ggg-3¢ and OCW77: 5¢-cgcggatcctcaccgcctcggcttgtc-3¢ and
cloned (KpnI±BamHI) into pcDNA3 (Invitrogen, Carlsbad,
CA) (pcDNA-hVEGF121). hVEGF121 was reampli®ed using
OWW134: 5¢-ggtctagaccaccatgaactttctgctg-3¢ and OWW135:
5¢-ctcgagtcaccgcctcgg-3¢ and ligated into pEF6/V5-His TOPO
(Invitrogen) (pWW276). pWW277 was constructed by excis-
ing hVEGF121 from pWW276 using XbaI±XhoI and cloning it
into pWW253. The prokaryotic CTA expression vector
pWW317 was constructed by ampli®cation of CTA from
pWW255 using OWW312: 5¢-cggaattcccaccatgcatatgaccac-
cgccgaccgc-3¢ and OWW313: 5¢-gctctagagcaagcttctacccaccg-
tactcgtcaattc-3¢ and ligation (NdeI±HindIII) into pRSETmod
[modi®ed pRSET vector (16)]. A 227 bp biotinylated
rheO-encoding DNA fragment was assembled by ampli®c-
ation of rheO using oligonucleotides OWW64: biotin-5¢-
ggggttccgcgcacatttcccc-3¢ and OWW22 (14) and pWW254
as template. All PCR products were con®rmed by DNA
sequencing.
Cell culture and reporter gene assays
The chicken bursal lymphoma cell line DT40 (ATCC
CRL-2111) was cultivated as described (17).
SAMY was quanti®ed as units per liter (U/l) as described
before (15), and hVEGF121 was assessed using a human VEGF
DuoSet enzyme-linked immunosorbent assay (ELISA; R&D
Systems, Minneapolis, MO; cat. no. DY293) according to the
manufacturer's protocol.
Electroporation of DT40 cells
For electroporation-based transfection, 5±8 3 105 exponen-
tially growing DT40 cells/ml were centrifuged at 450 g for
3 min, and 4 3 106 cells were resuspended in 0.4 ml of serum-
free RPMI-1640 medium. The cells were mixed with 30 mg of
DNA per plasmid and transferred to a Gene Pulser Cuvette
(Bio-Rad Laboratory AG, Glattbrugg, Switzerland; cat. no.
165-2088). Electroporation was performed using a Bio-Rad
Gene Pulser II and the following settings, resulting in
typical time constants of 45 ms: capacitance, 960 mF;
voltage, 360 V; resistance, R = ‘. Electroporation of
DT40 resulted in a typical transfection ef®ciency of
42 6 5%. After electroporation, the transfected cells were
diluted in 12 ml of complete RPMI-1640 medium and
cultivated as described.
Western blot analysis of CTA
A 1 ml culture from an Escherichia coli CTA production strain
was subjected to western blotting following detection using a
mouse anti-VP16 antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA; cat. no. sc-7545) and an anti-mouse
horseradish peroxidase (HRP)-coupled secondary antibody
as described below.
ELISA-based cell-free analysis of CTA±PCTA
interactions
For production of CTA, pWW317 (PT7-CTA-pA) was trans-
formed into E.coli BL21* (DE3)pLysS (Invitrogen; cat. no.
C6010-03) and transgenic E.coli strains were grown to an
OD600 of 1.2 prior to isopropyl-b-D-thiogalactopyranoside-
(1 mM) mediated induction for 3±4 h. Lysates were produced
by lysozyme treatment (0.2 mg/ml) for 45 min at 37°C and the
DNA was fragmented by sonication (®ve bursts of 2 s at 75 W
using a Branson Soni®er 450; Branson Ultrasonic Corp.,
Carouge, Switzerland). The supernatant was clari®ed by
centrifugation at 21 000 g for 30 min and 4°C. ELISA plates
(Corning, New York, NY; cat. no. 3590) were coated
overnight with 100 ml/well streptavidin solution (6 mg/ml) at
37°C while shaking at 250 r.p.m., and blocked for 2 h using
blocking solution [1% blocking reagent (Roche Molecular
Biochemicals, Rotkreuz, Switzerland; cat. no. 1-096-176) in
TBS (20 mM Tris±HCl, 150 mM NaCl, pH 7.6) and 10 mM
EDTA]. The blocking solution was removed and the plates
were washed four times with TBS±Tween (TBST). A 100 ml
aliquot of a 2 mg/ml solution containing biotinylated rheO-
encoding DNA in blocking solution was added per well and
incubated for 1 h. As in all subsequent incubation steps, the
sample was kept at 23°C and was shaken at 250 r.p.m. After
washing each well four times with 400 ml of pre-warmed
TBST, 30 ml of CTA-containing crude cell extract (containing
0.5 mg of CTA in 100 ml of protein in blocking solution)
was added per well, followed by incubation for 1 h. The wells
were washed four times with 400 ml of TBST, ®lled with
100 ml of blocking solution per well and incubated at different
temperatures for 1 h. After washing four times with 400 ml of
TBST pre-warmed at appropriate temperatures, the wells were
incubated with a 1:200 dilution of monoclonal mouse anti-
VP16 antibody (Santa Cruz Biotechnology; cat. no. sc-7545)
in blocking solution for 1 h. The primary antibody was
removed, and the wells were washed four times with 400 ml of
TBST and incubated for 30 min with the secondary HRP-
coupled anti-mouse IgG (Amersham Pharmacia Biotech,
Dubendorf, Switzerland; cat. no. NA931, lot. no. 168416)
diluted 1:200 in blocking solution without EDTA. The
chromogenic reaction was initiated by addition of 100 ml of
3,3¢,5,5¢-tetramethylbenzidine (TMB) substrate solution
(Sigma Chemicals, St Louis, MO; cat no. T-8665), stopped
by addition of 25 ml of 1 M H2SO4, and quanti®ed by
absorbance readings taken at 450 nm on a SpectraMax Plus
(Molecular Devices, Sunnyvale, CA).
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Microencapsulation of DT40 cells
At 20 h post-electroporation, DT40 cells were micro-
encapsulated in alginate±poly-L-lysine±alginate beads using
the Inotech Encapsulator Research IER-20 as previously
described (14). Microencapsulated DT40 cells were cultivated
in 10 ml of complete RPMI-1640 medium for 24 h at 41°C
prior to implantation into the chicken embryo (14,16).
Monitoring vascularization in chicken embryos
Experiments involving chicken embryos were conducted
following the shell-free cultivation protocols of Djonov
et al. (18). After 3 days of incubation at 37°C, Brown
Leghorn eggs were opened and their contents carefully poured
into plastic Petri dishes of 80 mm in diameter. The chicken
embryos were incubated further for 6 days at 37°C in a
humidi®ed atmosphere. On embryonic day 9, 50 ml of a
concentrated capsule solution (750 microcapsules containing
200 DT40 cells/capsule) containing microencapsulated DT40
cells engineered for TIGR-controlled hVEGF121 production
was injected under the chorioallantoic membrane (CAM) or
placed onto the CAM. The embryos were cultivated for a
further 2 days at 37 and 41°C, respectively. At embryonic day
11, the CAMs were examined by in vivo ¯uorescence
microscopy. Micrographs were taken following intravenous
injections of 100 ml of 2.5% ¯uorescein isothiocyanate
(FITC)±dextran 2 000 000 (Sigma Chemicals) (19). The
developing blood vessels were monitored using a Polyvar-
Reichert ¯uorescence microscope (Leica AG, Heerbrugg,
Switzerland) at 25-fold magni®cation. The microscope was
equipped with a custom-built heating table to maintain the
temperature of the specimens at the desired temperatures (37
or 41°C). Blood circulation and microvascular patterns were
monitored for 15 min for every CAM using a LE CCD
Optronics video camera (Visitron system, Puchheim,
Germany) and a digital video recorder (Sony, DHR-1000
VC, Sony AG, Schlieren, Switzerland).
Morphological analysis of vascularization
CAM samples were ®xed at embryonic day 11 in 2.5%
glutaraldehyde [buffered with 30 mM potassium phosphate
(370 mOsm; pH 7.4)], stained in 1% osmium tetroxide
[buffered with 0.1 M sodium cacodylate (340 mOsm; pH 7.4)],
dehydrated in ethanol, and embedded in Epon 812 as
described before (20). Sections 1 mm thick were prepared
using glass knives, stained with toluidine blue, and examined
on an Leitz DM-RBE light microscope (Leica AG, Heerbrugg,
Switzerland) equipped with a JVC KY-F70 video camera
(Spietzer Electronic AG, Oberwil, Switzerland). Furthermore,
80±90 nm thick sections were generated, transferred onto
Formvar-coated (polyvinyl formal; Fluka Chemie AG, Buchs,
Switzerland) copper grids, double-stained with lead citrate and
uranyl acetate, and monitored using a Philips EM 400
transmission electron microscope (18).
Methylmethacrylate (Mercoxâ) casting
Mercoxâ (Japan Vilene Company) casts of CAM vessels were
prepared at embryonic day 11. The vasculature was perfused
with a 0.9% sodium chloride solution containing 1%
Liqeminâ and Procaineâ, followed by a freshly prepared
Mercoxâ solution containing 0.1 ml of accelerator per 5 ml of
resin. At 2 h after perfusion, the CAMs were excised and
immersed in Ringer's solution for ~2 h and subsequently
transferred to 15% KOH for 2±4 weeks for dissolution of the
tissue. After washing, the casts were dehydrated in a graded
series of increasing ethanol concentrations and dried in a
vacuum desiccator (18). Samples were mounted on aluminum
stubs with carbon and sputtered with gold. They were
examined in a Philips XL 30 FEG scanning electron
microscope.
RESULTS
Design of the low temperature-inducible gene regulation
system
Previous design concepts of heterologous transgene control
systems for vertebrates/vertebrate cells included a regulating
small molecule that modulates the af®nity of an arti®cial
transactivator for its speci®c target promoter and thus adjusts
desired transgene expression in response to a molecule-
speci®c dosing regime (21,22). Unfortunately, many regulat-
ing agents proved to be toxic, elicited short- and long-term
side effects or have not yet been clinically licensed (21±25). In
order to avoid de®ciencies often found to be associated with
regulating small molecules, gene control systems that
could be ®ne-tuned by physical parameters such as tempera-
ture would represent a valuable alternative to current
technologies.
The generic cold-inducible transcription control system
consists of two chimeric genetic determinants, CTA and its
cognate promoter (PCTA). CTA was constructed by fusing the
S.albus heat shock response regulator RheA 3¢ to the herpes
simplex VP16 transactivation domain [CTA, RheA-VP16
(7,26)]. PCTA was assembled by cloning a RheA-speci®c
operator module (rheO, TGTCATCGTTCGGATGACA) 5¢
to a minimal version of the human cytomegalovirus
immediate early promoter [PhCMVmin; PCTA, rheO±PhCMVmin
(14,27)] (Fig. 1). Western blot analysis of CTA produced
in E.coli revealed a protein of 38 kDa correlating with
the deduced molecular weight of a full-length RheA-VP16
fusion protein (36.8 kDa) (pWW317, PT7-CTA-pA; data not
shown).
Thermosensitivity assessment of the CTA±PCTA
interaction using a cell-free assay
Investigation of whether CTA retains its RheA-typical
thermo-adjustable af®nity for rheO required the design of an
ELISA-based set-up tailored to quantify the CTA±PCTA
interaction in a cell-free assay. A biotin-labeled PCTA-
encoding PCR fragment immobilized on a streptavidin-coated
multi-well plate was incubated with the lysate of an E.coli
CTA production strain at varying temperatures prior to VP16-
targeted quanti®cation of CTA±PCTA interaction using a
standard colorimetric assay (Fig. 2). When con®gured in
this way, the ELISA demonstrated that decreasing binding
af®nity of CTA for PCTA correlated with increasing tempera-
tures (23, 25, 28, 31 and 37°C, Fig. 2). Thus, CTA has the
potential to function as a molecular thermometer that trans-
lates temperature changes into site-speci®c DNA-binding
capacity. Furthermore, since CTA has been designed as a
generic sequence-speci®c transcription activator, its binding to
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PCTA at low temperatures is expected to initiate transcription
of PCTA-driven transgenes in the absence of any exogenous
molecule.
Temperature-dependent ®ne-tuning of TIGR-driven
transgene expression in vertebrate cells
Since chicken cells show an unmatched range of cultivation
temperatures, we chose the chicken bursal lymphoma cell line
DT40 for validation of the TIGR technology in vertebrate cells
(17,28). When cloned into a vertebrate expression con®gur-
ation (pWW255, PhEF1a-CTA-pA) and transfected into DT40
cells, CTA production did not change the growth pro®le of the
chicken cell line, indicating that this chimeric transactivator
has no signi®cant impact on host cell physiology (doubling
times of 15.3 and 15.8 h for wild-type and CTA-expressing
DT40 cells cultivated at 41°C). When co-transfected with a
reporter plasmid encoding PCTA-driven SAMY [pWW254;
PCTA-SAMY-pA (15)], CTA transactivates SAMY at 37°C,
while expression of this reporter gene remains silent at 41°C
(Fig. 3). CTA-mediated transactivation of PCTA results in
expression levels comparable with wild-type PhEF1a, which
itself remains insensitive to temperature changes (Fig. 3). In
principle, TIGR-controlled gene expression also works in
mammalian cells, as exempli®ed by CHO cells transfected by
TIGR-controlled SAMY expression (34°C, 90 6 11 U/l; 41°C,
34 6 8.7 U/l).
Figure 1. TIGR system. Top three expression units show the molecular
details of TIGR. The cold-inducible transactivator (CTA) was constructed
by fusing the S.albus heat shock response regulator rheA to the VP16 trans-
activation domain of herpes simplex virus (CTA, rheA-VP16). CTA was
placed under control of the human elongation factor 1-a promoter, which
mediates constitutive high level expression in chicken cells (pWW255,
PhEF1a-CTA-pA). The CTA-responsive target promoter PCTA was assembled
by cloning a single rheA-speci®c operator module (rheO) adjacent to a
minimal version of the human cytomegalovirus immediate early promoter
(PhCMVmin) (PCTA, rheO-PhCMVmin). PCTA was con®gured to drive either the
cDNA encoding the human vascular endothelial growth factor A
(hVEGF121; pWW277, PCTA-hVEGF121-pA) or the SAMY reporter gene
(pWW254, PCTA-SAMY-pA). Selected sites for restriction endonucleases
are indicated. Bottom two expression units illustrate TIGR-controlled trans-
gene expression at different temperatures. At the permissive temperature of
37°C, CTA binds and transactivates PCTA, which results in expression of the
gene of interest. At 41°C, the PCTA binding af®nity of CTA is abolished and
expression of the gene of interest remains silent.
Figure 2. ELISA-based quanti®cation of the thermosensitivity of the
CTA±PCTA interaction. (A) Schematic representation for scoring the CTA
af®nity for PCTA. A PCR-generated biotin (BT)-labeled PCTA fragment is
immobilized via streptavidin (ST) in a multi-well chamber. This set-up is
incubated with the lysate of an E.coli CTA production strain (harboring
pWW317, PT7-CTA-pA) at different temperatures. After washing steps, the
af®nity of CTA for PCTA is quanti®ed by anti-VP16-based immunodetection
visualized by an HRP-conjugated secondary antibody (targeted against the
Fc region of the anti-VP16 antibody) which converts TMB into a color
readout at 450 nm. (B) Quantitative ELISA-based cell-free analysis of
CTA±PCTA interaction at different temperatures. Whereas CTA showed
lower af®nity for its cognate rheO operator module at increasing tempera-
tures (black bars), the interaction of the control con®guration consisting of
the macrolide-responsive transactivator (ET1) and its target sequence ETR
was insensitive to temperature changes (white bars). Furthermore, the CTA
binding capacity was speci®c for rheO as it did not interact with the ETR
operator module at any of the temperatures (shaded bars).
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Beyond simple switch on and off characteristics, TIGR-
controlled SAMY expression was adjustable and could be
®ne-tuned to any desired level following incubation of
engineered DT40 cell lines at intermediate temperatures
(doubling times: 37°C, 20.8 h; 38°C, 15.8 h; 39°C, 15.6 h;
40°C, 15.4 h; 41°C, 15.3 h). In this con®guration, the
molecular thermometer CTA could reliably translate tem-
perature changes of a degree with unmatched precision into
desired transgene expression levels (Fig. 4). Interestingly, the
temperature range effective for modulating the CTA±PCTA
interaction varies signi®cantly between cell-free (37±23°C)
and cell-based systems (41±37°C). Thus, RheA fusions
partners and/or cell-speci®c protein cocktails interacting
with fused domains are expected to modify RheA's respon-
siveness to temperature, which will enable precise adaptation
of the TIGR system to a desired cellular context or
temperature range.
The TIGR con®guration based on two plasmids encoding
constitutive CTA and PCTA-driven transgene expression units
was further re®ned by designing a one-vector-based auto-
regulated cold-inducible expression unit. This autoregulated
set-up consisted of a PCTA-controlled dicistronic expression
cassette encoding SAMY in the ®rst and CTA in the second
cistron [pWW259, PCTA-SAMY-IRES-CTA-pA; IRES,
internal ribosome entry site of polioviral origin (29)]. Leaky
PCTA-driven dicistronic transcript results in few CTAs that
initiate a positive feedback loop, resulting in high level
expression of the transactivator as well as the co-cistronically
encoded reporter gene SAMY at permissive temperatures.
Besides its compact one-vector con®guration, the autoregu-
lated expression set-up compares favorably with the binary
TIGR design (autoregulated: 41°C, 5.8 6 0.2 U/l; 37°C,
65.1 6 4.3 U/l; binary: 41°C, 4.4 6 0.1 U/l; 37°C,
56.5 6 3.6 U/l).
TIGR-controlled production of human VEGF following
implantation of microencapsulated and transfected DT40
cells into chicken embryos
For validation of the low-temperature-induced gene expres-
sion system in vivo, we chose to transplant DT40 cells
transfected for TIGR-controlled hVEGF121 into chicken
embryos (pWW255, PhEF1a-CTA-pA; pWW277, PCTA-
hVEGF121-pA). Since direct sub-CAM implantation of
DT40 cells was lethal for the chicken embryos in initial
experiments, we encapsulated the DT40 cell derivatives in
alginate±poly-L-lysine±alginate beads. Microencapsulated
TIGR-responsive hVEGF121 production cell lines showed
identical temperature induction pro®les and maximum expres-
sion levels of this growth factor, indicating that encapsulation
does not impair the overall regulation performance of the
TIGR system (non-encapsulated DT40: 41°C, 25.9 6
3.5 ng/ml; 37°C, 168 6 19 ng/ml; encapsulated DT40:
41°C, 21.9 6 0.6 ng/ml; 37°C, 171 6 19 ng/ml). hVEGF121
produced in chicken cells is glycosylated in a different manner
compared with mammalian cells (data not shown).
Microencapsulated DT40 cells engineered for TIGR-
controlled hVEGF121 expression were implanted into chicken
embryos and placed onto the CAM. The chicken embryos
were grown at 37 and 41°C for 2 days prior to microscopical
analysis of the vascularization of the CAM. hVEGF121-
mediated vascularization could only be monitored in chicken
embryos incubated at 37°C, whereas control embryos con-
taining capsules only or capsules with non-engineered DT40
cells displayed a regular wild-type pattern of blood vessels,
which was insensitive to temperature changes (Fig. 5).
Constitutive hVEGF121 expression in DT40 cells transplanted
into chicken embryos cultivated at 41°C showed vasculariz-
ation patterns comparable with TIGR-controlled growth factor
production at 37°C, indicating that hVEGF121 remains active
at elevated temperatures (data not shown).
DISCUSSION
Gene±function correlations are one of the major challenges in
the post-genomic era. Owing to their unmatched gene
targeting frequencies, stability and easy handling, the chicken
bursal B-cell line DT40 has become a cornerstone in recent
Figure 4. Temperature adjustability of the TIGR system. DT40 cells co-
transfected with pWW255 (PhEF1a-CTA-pA) and pWW254 (PCTA-SAMY-
pA) were incubated at varying temperatures, and SAMY production pro®les
were quanti®ed at different time points post-transfection.
Figure 3. TIGR-mediated temperature-dependent transgene expression
switches in chicken DT40 cells. Triplicate DT40 cultures were co-trans-
fected with the CTA expression construct pWW255 (PhEF1a-CTA-pA) as
well as the CTA-responsive SAMY expression vector pWW254 (PCTA-
SAMY-pA) and incubated at 37 and 41°C. At 48 h post-transfection,
SAMY expression pro®les were quanti®ed in the supernatant of both
cultures. DT40 control cells transfected with the constitutive SAMY expres-
sion vector pSS211 (PhEF1a-SAMY-pA; S.Schlatter, unpublished) showed
similar reporter gene expression pro®les at both temperatures.
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reverse genetics initiatives (28,30). For example, DT40 cells
have been essential for the elucidation of immunoglobulin
somatic hypermutation and af®nity maturation of antibodies,
gene conversion, homologous recombination, RNA editing
and the design of arti®cial chromosomes (17,31±35). Also,
recent advances in the production of protein pharmaceuticals
in the egg white of transgenic chickens and the use of chicken
embryos for validation of tissue engineering and therapeutic
Figure 5. hVEGF121-mediated vascularization in chicken embryos. Parallel grafting experiments were performed following supra-CAM application of micro-
encapsulated DT40 cells engineered for TIGR-controlled hVEGF121 and incubation at 41°C (a, c, e and g) and 37°C (b, d, f and h) for 2 days (until embryonic
day 11). (a±d) Still video images of the growing CAM microvasculature at embryonic day 11 (application site indicated by asterisks) following intravenous
injection of FITC±dextran (a and b overview; c and d insets of a and b at higher magni®cation). As shown in (b) and (d) in comparison with (a) and (c), only
TIGR-mediated induction of hVEGF121 at 37°C results in a massive angiogenic response exempli®ed by (i) the increased number of the feeding vessels; and
(ii) their tortuous shape (arrows shown in d) and the formation of arterial venous shunts (arrowhead in d). Scanning electron micrographs con®rm increased
numbers of arterioles and veins as well as a densely packed capillary plexus in CAMs incubated at 37°C (f) when compared with an isogenic set-up grown at
41°C (e). Cross-sections through microcapsules and underlying CAM reveal a local angiogenic response at sites of application at 37°C (h) but not at 41°C
(g). The wild-type CAM consisting of capillary plexus (arrows in g) in the subepithelial region is transformed by TIGR-controlled production of hVEGF121 at
permissive temperatures into a compact and stacked multitude of newly formed capillary vessels (arrows in h). The supplying vessels are indicated by
asterisks. Size bars: (a) and (b) = 50 mm; (c), (d), (e) and (f) = 200 mm, (g) and (h) = 20 mm.
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angiogenesis concepts puts the DT40 chicken model system
into the limelight of basic and applied research (36±38).
Rational reprogramming of vertebrate cells by conditional
molecular interventions has generated dramatic impact on
gene±function analysis (39,40), prototype gene therapy
scenarios (14,41,42), tissue engineering (43), design of animal
models with human disease phenotypes (40,44,45), drug
discovery (46) and biopharmaceutical manufacturing (47±49).
A variety of heterologous small molecule-responsive gene
regulation systems have been designed, improved and valid-
ated in different cell culture and in vivo settings (21,22).
Although most available heterologous gene control systems
have shown excellent performance in modulating desired
transgene expression in basic research settings, the use of
many of these gene switches in biopharmaceutical manufac-
turing, gene therapy or tissue engineering may be limited due
to a combination of low or leaky expression, side effects of
regulating molecules, and incompatibilities with regulatory
guidelines. Antibiotic-responsive gene regulation systems
(14,27,50,51) and the chemically induced dimerization tech-
nology (52), which are currently competing for clinical
applications, combine most assets of ideal gene control
modalities: (i) regulation by a clinically licensed, bioavailable
molecule devoid of long-term side effects; (ii) low leaky
expression and high induction levels; (iii) optimal dose±
response characteristics; (iv) compact, preferably one-vector
design; and (v) low immunogenicity. Yet accumulation of
antibiotics in bone and teeth following long-term administra-
tion (23,25) and the long-awaited clinical approval of non-
immunosuppressive dimerizer drugs put these systems on hold
for many therapeutic settings (14,27,51,52). Furthermore,
precise in vivo dosing of regulating molecules remains a
challenge, as most currently available gene control systems
are only adjustable within a narrow drug concentration
window (14,27,51,52). The combination of reliable hetero-
logous gene control con®gurations with physiological non-
molecule inducers might represent a decisive advancement for
the gene regulation territory.
Gene switches induced by a temperature downshift display
a high degree of physiological compatibility since low-
temperature cultivation is well tolerated by vertebrate cells
and typically associated with increased speci®c productivity
(53). In principle, any protein can be mutated to become
temperature sensitive. For example, speci®c mutations ren-
dered the RNA-dependent RNA replicase of alphaviruses
temperature sensitive. Following a temperature downshift
from 37 to 29°C, the viral replicase initiates an RNA
ampli®cation loop resulting in high level expression of desired
transgenes driven by subgenomic viral promoters (54,55).
Concerns about safety, long-term cytopathy and accumulation
of mutations in product proteins produced by a viral replicase
devoid of any proof-reading capacity have so far limited the
use of this technology beyond basic research.
TIGR includes the ®rst vertebrate thermosensor, which
recruits the endogenous transcription initiation machinery for
temperature-adjustable transgene expression. TIGR exhibits
rapid response kinetics typically associated with natural
temperature switches, low basal expression near the detection
limit, high maximum expression levels comparable with
PhEF1a, one of the strongest vertebrate promoters, and
induction ratios compatible with state-of-the-art conditional
molecular interventions in vertebrate cells (40,56). The TIGR
performance was successfully tested in an in vivo angiogenesis
model: TIGR promoted solid high level expression of human
hVEGF121 in chicken embryos at 37°C, while expression of
this key angiogenic factor was completely neutralized as
evidenced by wild-type-like vascularization at 41°C.
VEGF and its various splice variants are the most prominent
representatives among angiogenic growth factors that induce
new blood vessels from pre-existing vasculature. VEGF plays
an essential role in embryonic development, normal growth of
tissues, wound healing and the female reproductive cycle
(38,57±59). The fact that the slightest disregulation of
endogenous VEGF expression is associated with severe
pathologies, upregulation with neoplasia and downregulation
with ischemia, explains why production of this growth factor
is tightly regulated at multiple levels (38,57±59). Therefore, it
is not surprising that VEGF has been a 2-fold therapeutic
target, and strategies to inhibit this growth factor or its targeted
administration are currently in clinical trials. Although
therapeutic angiogenesis achieved promising results in
chronic myocardial and retinal ischemia, uncontrolled sys-
temic delivery has been associated with hypotension, edema,
accelerated atherosclerosis and endothelial cell-derived
tumors (38,58,60). Milestones in adjustable therapeutic
delivery of VEGF included third-generation biomaterials
supporting wound healing by controlled release of recom-
binant hVEGF and regulation of endogenous VEGF using a
dimerization-dependent arti®cial transactivator targeted to the
VEGF promoter region (61±63).
As of now, TIGR-based transcription control represents the
®rst non-viral thermosensor for controlled transgene expres-
sion in vertebrates. Because of the simplicity of its inducer, i.e.
temperature, TIGR will probably foster advances in pro®table
biopharmaceutical manufacturing of dif®cult to produce
protein therapeutics and the understanding of angiogenesis.
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